---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000027"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-08-12T20:13:33+00:00"
generated_at: "2026-08-12T20:14:05.655281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials

## Summary
- Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).
- Cash, equivalents, short-term investments $31.5M at June 30, 2026; runway at least one year.
- Enrollment completed in Phase 2 Seabreeze STAT asthma (160 pts) and COPD (159 pts) studies; topline results expected September 2026.
- Initiated open-label Phase 2 Seabreeze STAT IV trial (40 participants) evaluating IV rademikibart for acute exacerbations.
- Simcere license revenue $2.8M in Q2 (vs $48K prior year); eligible for up to ~$99M in remaining milestones.

## SEC filing metadata
- accession: 0001835268-26-000027
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-08-12T20:13:33+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/0001835268-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntb-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000027
- JSON: https://secwatch.observer/filing/0001835268-26-000027.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.